Director Kaye receives 197 Cytokinetics (NASDAQ: CYTK) shares as pay

Rhea-AI Filing Summary

Cytokinetics director Edward M. Kaye, M.D. reported receiving additional company stock as part of his board compensation. On 01/15/2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. According to the filing, these were fully vested shares issued in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this transaction, Dr. Kaye directly owned 10,174 shares of Cytokinetics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		A(1)		197	A	$63.44	10,174	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of our Board of Directors.

	/s/ John Faurescu, attorney-in-fact for Dr. Kaye	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cytokinetics (CYTK) report for Dr. Edward M. Kaye?

Dr. Edward M. Kaye reported acquiring 197 shares of Cytokinetics common stock on 01/15/2026, reported on a Form 4.

At what price were the new Cytokinetics (CYTK) shares acquired by Dr. Kaye?

The 197 shares of Cytokinetics common stock were acquired at a price of $63.44 per share.

How many Cytokinetics (CYTK) shares does Dr. Kaye own after this Form 4 transaction?

Following the reported transaction, Dr. Edward M. Kaye directly beneficially owned 10,174 shares of Cytokinetics common stock.

Was the Cytokinetics (CYTK) Form 4 transaction a stock purchase or compensation?

The filing states the fully vested shares were received in lieu of a cash retainer, as part of an equity compensation option for board members.

What is Dr. Kaye’s relationship to Cytokinetics (CYTK)?

Dr. Edward M. Kaye is reported as a Director of Cytokinetics and is not listed as an officer or 10% owner in this filing.

Is Dr. Kaye’s ownership in Cytokinetics (CYTK) direct or indirect?

The Form 4 indicates that Dr. Kaye’s 10,174 shares are held with direct (D) ownership.